Closed
NHS National Framework for Trastuzumab 600mg Subcutaneous Injection
NHS England
- Value
- £102,960,000
- Published
- 5 Aug 2026
- Deadline
- 19 Aug 2026
- Procedure
- Not stated
- Category
- 33600000 — Pharmaceutical products
- Location
- UKC, United Kingdom
- Notice reference
- 074125-2026
Requirements summary
NHS England is planning a national framework agreement for supply of Trastuzumab 600mg subcutaneous injection, a pharmaceutical product, under offer reference CM/TNS/26/5762. The framework period runs from 1 June 2027 to 31 August 2028, with options to extend up to 24 months in total, and the estimated value is GBP 102,960,000 gross (GBP 85,800,000 net). The notice is a preliminary market engagement stage, inviting current and potential suppliers planning to launch relevant molecules to register interest.
Key requirements
- Framework supply of Trastuzumab 600mg subcutaneous injection (Lot 1)
- Framework period 1 June 2027 to 31 August 2028, with extension options up to 24 months total
- Delivery across listed English regions (UKC, UKD, UKF, UKG, UKH, UKJ, UKK)
- Estimated value GBP 102.96m gross (GBP 85.8m net)
- Suppliers may need to confirm product launch timing within the framework period
- Tender structure and KPIs to be discussed at preliminary market engagement; SME suitability indicated
Similar open notices
- NHS National Framework Agreement for Macitentan & Cladribine TabletsNHS England
- NHS National Framework Agreement for Macitentan & Cladribine TabletsNHS England
- Injection Equipment ParaphernaliaThe Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)
- Framework for the Provision of Dose Banded Products & Patient Specific Chemotherapy ServicesUniversity Hospitals of Derby and Burton NHS Foundation Trust
- NEYPPC Pharmacy - Unlicensed Imported Medicines (wave 2)Leeds Teaching Hospitals NHS Trust